Meeting the Challenges in Atrial Fibrillation Management: The Role of New Anticoagulants - European Medical Journal

Meeting the Challenges in Atrial Fibrillation Management: The Role of New Anticoagulants

Download PDF
Freek Verheugt,1 Christoph Bode2
Gregory Lip,3 Raffaele De Caterina,4 Robert Giugliano5

Prof Gregory Lip has acted as a consultant for Bayer, Astellas, Merck, Sanofi, BMS/Pfizer, Biotronik, Medtronic, Portola, Boehringer Ingelheim, Microlife Medtronic, and Daiichi Sankyo. He has also been on the speakers’ bureau for Bayer, BMS/Pfizer, Medtronic, Boehringer Ingelheim, Microlife, and Daiichi Sankyo. Prof Raffaele De Caterina has received fees, honoraria, and research funding from Sanofi-Aventis, Boehringer Ingelheim, Bayer, BMS/Pfizer, Daiichi Sankyo, and Novartis. Prof Robert Giugliano has received research grant support from Daiichi Sankyo and Merck, and honoraria for lectures/consulting from Daiichi Sankyo, Merck, Janssen, Pfizer, and Sanofi.


Writing assistance provided by Dr Saroshi Amirthalingam, apothecom scopemedical Ltd.


The publication of this article was funded by Daiichi Sankyo Europe GmbH. The views and opinions expressed are those of the authors and not necessarily of Daiichi Sankyo.

EMJ Cardiol. ;2:38-45. DOI/10.33590/emjcardiol/10311237.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Meeting Summary

Prof Gregory Lip opened the symposium with a discussion on determining stroke and bleeding risk in atrial fibrillation (AF) patients and their management. Prof Raffaele De Caterina presented data from the PREFER in AF registry and trends in the management of AF across Europe. Dr Robert Giugliano concluded with a presentation of the latest data from the ENGAGE AF-TIMI 48 trial.

Please view the full content in the pdf above.

Join our mailing list

To receive the EMJ updates straight to your inbox free of charge, please click the button below.
Join Now